Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Unstable Angina.

Murad1, Henry

  • 1Division of Cardiovascular Medicine, Hennepin County Medical Center, 701 Park Avenue South, Minneapolis, MN 55415, USA.

Current Treatment Options in Cardiovascular Medicine
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resection of the Lower Jaw.

Western journal of medicine and surgery·2024
Same author

Corrigendum to "A new innovative breakthrough in the production of salt from bittern using a spray dryer" [Heliyon 8 (10) (2022) e11060].

Heliyon·2023
Same author

Cytotoxicity of phenylpironetin analogs and the metabolic fate of pironetin and phenylpironetin.

Bioorganic chemistry·2022
Same author

Account of Two Cases of Tic Douloureux, Cured by the External Use of the Atropa Belladonna.

The London medical and physical journal·2018
Same author

Considerations on infant otomastosis.

Gazette medicale de France·2010
Same author

Tinnitus Cognitions Questionnaire: Development and Psychometric Properties of a Measure of Dysfunctional Cognitions Associated with Tinnitus.

The international tinnitus journal·2001
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
See all related articles

Novel antiplatelet and antithrombin therapies offer improved treatment for unstable angina (UA). Glycoprotein (GP) IIb/IIIa inhibitors, low-molecular-weight heparin (LMWH), and direct thrombin inhibitors show promise in reducing cardiac events.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Unstable angina (UA) management has evolved with new antiplatelet and antithrombin agents.
  • Current guidelines suggest aspirin, unfractionated heparin (UFH), and antianginal therapy for UA.
  • Novel agents like low-molecular-weight heparin (LMWH) and direct thrombin inhibitors offer advantages over UFH.

Purpose of the Study:

  • To review the therapeutic options for intermediate- and high-risk unstable angina.
  • To discuss the role of novel antiplatelet and antithrombin agents in UA management.
  • To evaluate the benefits of Glycoprotein (GP) IIb/IIIa receptor inhibition and coronary revascularization.

Main Methods:

  • Review of current guidelines and clinical trial data.
  • Discussion of pharmacological agents including aspirin, UFH, LMWH, direct thrombin inhibitors, and GP IIb/IIIa inhibitors.

Related Experiment Videos

  • Analysis of the role of early invasive strategies and coronary revascularization.

    • Main Results:

    • Glycoprotein (GP) IIb/IIIa inhibition reduces myocardial infarction (MI) risk and mortality in UA.
    • LMWH and direct thrombin inhibitors are viable alternatives to UFH in selected patients.
    • The combination of GP IIb/IIIa inhibitors with aspirin and UFH is beneficial in early invasive approaches.

    Conclusions:

    • New antiplatelet and antithrombin agents have significantly improved UA treatment.
    • Further research is needed on LMWH combined with GP IIb/IIIa inhibitors and during percutaneous transluminal coronary angioplasty (PTCA).
    • The goal is to reduce serious cardiac events through potent drug combinations for early control of thrombosis.